Search Result

Results for "

cytochrome P450 3A4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (21) 5-HT Receptor (4) Apoptosis (3) Autophagy (8) Bacterial (1) Calcium Channel (1) Dopamine Receptor (3) Drug Metabolite (6) Endogenous Metabolite (1) FGFR (1) Fluorescent Dye (1) Fungal (2) HIV (1) HSV (1) Isotope-Labeled Compounds (3) Parasite (2) Potassium Channel (2) PPAR (6) Reverse Transcriptase (1) SARS-CoV (2) SGLT (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (8) Endocrinology (1) Infection (8) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (6)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Cytochrome P450

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100638A

RPR132595A hydrochloride NPC hydrochloride	Drug Metabolite	Cancer
RPR132595A (NPC) hydrochloride is an active metabolite of CPT-11, which is generated by **cytochrome P-450 3A4 (CYP3A4)** and finally excreted through urine .

HY-135161

EDDP perchlorate	Drug Metabolite	Others
EDDP perchlorate is an N-desmethyl metabolite of Methadone by intestinal, hepatic, and cytochrome P450 (CYP) 3A4 .

HY-150574

CYP3A4-IN-1	Cytochrome P450	Infection
CYP3A4-IN-1 (compound 5a) is a potent **cytochrome P450 3A4 (CYP3A4) inhibitor with an IC₅₀** value of 0.085 µM .

HY-N10421

Dihydrocubebin (-)-Dihydrocubebin	Others	Others
Dihydrocubebin is a compound isolated from Piper cubeba as potent and selective inhibitors against cytochrome P450 3A4 (CYP3A4) .

HY-100638

RPR132595A NPC	Drug Metabolite	Cancer
RPR132595A (NPC) is an active metabolite of CPT-11, which is generated by **cytochrome P-450 3A4 (CYP3A4)** and finally excreted through urine .

HY-126983

6',7'-Epoxybergamottin Epoxybergamottin	Others Endogenous Metabolite	Others
6',7'-Epoxybergamottin is a metabolism of Penicillium digitatum. 6',7'-Epoxybergamottin can be used in study the cytochrome **P450 3A4** inhibitory activity .

HY-117010

Kushenol K	Cytochrome P450 HSV SGLT	Infection Metabolic Disease
Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a **cytochrome P-450 3A4 (CYP3A4) inhibitor with a K_i value of 1.35 μM . Kushenol K shows weak antiviral activity against HSV-2 (EC₅₀ of 147 μM) . Kushenol K also inhibits the activity of SGLT1 and SGLT2** .

HY-150581

CYP3A4-IN-3	Cytochrome P450	Infection Inflammation/Immunology
CYP3A4-IN-3 is a high-affinity specific inhibitor of **cytochrome P450 3A4 (CYP3A4) with the IC₅₀** value of 0.075 μM. CYP3A4-IN-3 is a ritonavir analogue, but with a simpler structure and twice the inhibitory effect of ritonavir. CYP3A4-IN-3 is used as an antiviral agent and immunosuppressant .

HY-150580

CYP3A4-IN-2	Cytochrome P450	Inflammation/Immunology Cancer
CYP3A4-IN-2 is a specific inhibitor of **cytochrome P450 3A4 (CYP3A4) with the IC₅₀** value of 0.055 μM. CYP3A4-IN-2 is a ritonavir analogue with increased hydrophobicity of the R2 side group and stronger inhibitory effect compared to ritonavir. CYP3A4-IN-2 can be used as an antiviral agent and immunosuppressants .

HY-133152

Brexpiprazole S-oxide DM-3411	5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT_1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT_2A receptor antagonist with a K_i of 0.47 nM .

HY-133152S

Brexpiprazole S-oxide-d8 DM-3411 d₈	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide-d₈ is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM[1][2][3].

HY-137580

N-Desmethyl Eletriptan	Others	Metabolic Disease
N-desmethyl Eletriptan is a metabolite of Eletriptan (HY-A0039). It is formed from eletriptan primarily by the cytochrome P450 (CYP) isoform CYP3A4 in human liver microsomes.

HY-N8094

Kushenol M	Cytochrome P450	Others
Kushenol M is a flavonoid from Sophora flavescens. Kushenol M is a cytochrome P450 (CYP) inhibitor, with IC₅₀ values of 1.29 μM for CYP3A4 in human liver microsomes .

HY-149977

Anticancer agent 111	Cytochrome P450	Cancer
Anticancer agent 111 (compound 11) is a potent **cytochrome P450 inhibitor with an IC₅₀** value of 3 μM for CYP3A4. Anticancer agent 111 has anticancer activity. Anticancer agent 111 can be used in research of cancer .

HY-W739812

Carboxy finasteride Finasteride carboxylic acid	Others	Cancer
Carboxy finasteride is a metabolite of the 5α-reductase inhibitor Finasteride (HY-13635). Finasteride is biotransformed by cytochrome P450 (CYP3A4) and is successively oxidized to Hydroxy finasteride and Carboxy finasteride. Carboxy finasteride is the major metabolite in urine, while Hydroxy finasteride is the major metabolite in plasma .

HY-14294

Capravirine S-1153	Reverse Transcriptase HIV	Infection
Capravirine (S-1153) is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent antiviral activity. Capravirine inhibits replication of HIV-1 strains that are resistant to nucleoside/nucleotide reverse transcriptase inhibitors and other NNRTIs. Capravirine is metabolized by the cytochrome P450 enzyme CYP3A4 .

HY-124542

5-Hydroxydiclofenac	Drug Metabolite Apoptosis	Cancer
5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .

HY-127059

Clindamycin Sulfoxide U-25026A	Others	Metabolic Disease
Clindamycin sulfoxide is an active metabolite of the antibiotic Clindamycin (HY-B1455). It is formed via S-oxidation of clindamycin primarily by the cytochrome P450 (CYP) isoform CYP3A4. Clindamycin sulfoxide inhibits the growth of P. prevotti, B. fragilis, and C. sordelli in vitro with MIC values of 2, 2, and 1 mg/L, respectively.

HY-135390

Hydroxy desmethyl Bosentan Ro 64-1056	Drug Metabolite	Cardiovascular Disease
Hydroxy desmethyl Bosentan (Ro 64-105) is a Bosentan metabolism produced by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver . Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively. Bosentan can be used in treatment of pulmonary arterial hypertension .

HY-113031

16a-Hydroxydehydroisoandrosterone 16α-Hydroxy-DHEA; 16α-OH-DHEA; 16α-hydroxy DHEA	Others	Endocrinology
16α-hydroxy Dehydroepiandrosterone is a metabolite of the endogenous steroid hormone dehydroepiandrosterone. 16α-hydroxy Dehydroepiandrosterone is formed from dehydroepiandrosterone via 16-hydroxylation by the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in adult human liver microsomes, as well as by fetal recombinant CYP3A7. It is a precursor to fetal estrogens, including estriol.

HY-17356

Fenofibrate Maximum Cited Publications 17 Publications Verification	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-W011235

Norfluoxetine hydrochloride	5-HT Receptor Calcium Channel Drug Metabolite	Cardiovascular Disease Neurological Disease
Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-150084

(±)14,15-Epoxyeicosatrienoic acid (±)14(15)-EET	Cytochrome P450	Cancer
(±)14,15-Epoxyeicosatrienoic acid ((±)14(15)-EET) is the Cytochrome P450 metabolite of arachidonic acid. While CYP3A4 may be involved in breast cancer cell growth, (±)14,15-Epoxyeicosatrienoic acid may promote mitosis and anchorage-dependent cloning through STAT3 affected by CYP3A4. (±)14,15-Epoxyeicosatrienoic acid exhibits STAT3-dependent cell growth promotion and may also participate in the autocrine/paracrine pathway that drives cell growth .

HY-147999

GlcN-6-P Synthase-IN-1	Bacterial Fungal Cytochrome P450	Infection
GlcN-6-P Synthase-IN-1 (Compound 4d) is a Glucosamine-6-phosphate (GlcN-6-P) synthase inhibitor with an IC₅₀ of 3.47 μM. GlcN-6-P Synthase-IN-1 exhibits significant antimicrobial activity. GlcN-6-P Synthase-IN-1 has good penetration in the CNS and is able to inhibit the **cytochrome P450, CYP3A4** isoform .

HY-17356S1

Fenofibrate-d4	PPAR Autophagy Cytochrome P450	Cardiovascular Disease
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-17356R

Fenofibrate (Standard) Maximum Cited Publications 17 Publications Verification	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-17356S2

Fenofibrate-13C6	Isotope-Labeled Compounds Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-169119

Antifungal agent 114	Cytochrome P450 Fungal	Infection
Antifungal agent 114 (Compound 19g) is an inhibitor for **Cytochrome P450*, that inhibits CYP1A2, CYP2C9, CYP2C19 CYP2D6 and CYP3A4 at 10 μM. Antifungal agent 114 exhibits antifungal activity against Cryptococcus neoformans, Candida* and Aspergillus, with MIC <0.0625 μg/mL. Antifungal agent 114 exhibits good metabolic stability in human liver microsomes with a half-time of 107 minutes .

HY-116862

Dibenzylfluorescein DBF	Cytochrome P450 Fluorescent Dye	Others
Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 µM (Ex=485nm，Em=535nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-131527

Wy-45494 hydrochloride N-Desmethyl Venlafaxine hydrochloride; Wy 45494	Others	Metabolic Disease
Wy-45494 hydrochloride (N-Desmethyl Venlafaxine hydrochloride; Wy 45494) is a minor active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine. It is formed from venlafaxine via the cytochrome P450 (CYP) isomer CYP3A4.2. Wy-45494 hydrochloride inhibits norepinephrine and serotonin reuptake in rat synaptosomal preparations (IC₅₀s of 4.7 and 1.6 μM, respectively). In vivo, Wy-45494 hydrochloride reversed reserpine-induced hypothermia in mice at a minimum effective dose (MED) of 10 mg/kg.

HY-148597

FGFR-IN-10	FGFR Cytochrome P450	Cancer
FGFR-IN-10 is an orally active inhibitor of FGFR and **Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC₅₀s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC₅₀**s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively .

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-18063

ML252	Potassium Channel Cytochrome P450	Neurological Disease
ML252 is a selective inhibitor of KCNQ2 (Kv7.2) channel with an IC₅₀s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 also inhibits **Cytochrome P450 with IC₅₀**s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant .

HY-18063A

ML252 hydrochloride	Potassium Channel Cytochrome P450	Neurological Disease
ML252 hydrochloride is a selective inhibitor of KCNQ2 (Kv7.2) channel with IC₅₀s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 hydrochloride also inhibits **Cytochrome P450 with IC₅₀**s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 hydrochloride shows highly brain penetrant .

HY-100057

BMY 28674 6-Hydroxybuspirone; 6'-Hydroxybuspirone; BMS 528215	5-HT Receptor Dopamine Receptor	Neurological Disease
BMY 28674 (6-Hydroxybuspirone) is the active metabolite of the anxiolytic buspirone. It is formed from buspirone via the cytochrome P450 (CYP) isozyme CYP3A4.4. BMY 28674 binds to the serotonin (5-HT) receptor subtype 5-HT1A in the rat hippocampus and dorsal raphe (EC₅₀s are 4 and 1 μM, respectively) and is an antagonist of dopamine D2, D3, and D4 receptors (IC₅₀s are 3.1, 4.9, and 0.85 μM, respectively). It also inhibits organic cation transporter 1 (OCT1), OCT2, and OCT3 expressing human transporters in S2 proximal tubule cells in a concentration-dependent manner.

HY-N6972

Cepharanthine 4 Publications Verification	Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite	Infection Inflammation/Immunology Cancer
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 µM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-N6972R

Cepharanthine (Standard)	Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite	Infection Inflammation/Immunology Cancer
Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

Cat. No.	Product Name	Type

HY-116862

Dibenzylfluorescein DBF	Fluorescent Dyes/Probes
Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 µM (Ex=485nm，Em=535nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

Dibenzylfluorescein

DBF

Fluorescent Dyes/Probes

Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 µM (Ex=485nm，Em=535nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-17356G

Fenofibrate (GMP)	Fluorescent Dye
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

Fenofibrate (GMP)

Fluorescent Dye

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)	Biochemical Assay Reagents
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

Fenofibrate (GMP)

Biochemical Assay Reagents

(±)14,15-Epoxyeicosatrienoic acid (±)14(15)-EET	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Cytochrome P450
(±)14,15-Epoxyeicosatrienoic acid ((±)14(15)-EET) is the Cytochrome P450 metabolite of arachidonic acid. While CYP3A4 may be involved in breast cancer cell growth, (±)14,15-Epoxyeicosatrienoic acid may promote mitosis and anchorage-dependent cloning through STAT3 affected by CYP3A4. (±)14,15-Epoxyeicosatrienoic acid exhibits STAT3-dependent cell growth promotion and may also participate in the autocrine/paracrine pathway that drives cell growth .

Cepharanthine 4 Publications Verification	Infection Structural Classification Alkaloids Stephania cepharantha Hayata Classification of Application Fields Plants Isoquinoline Alkaloids Menispermaceae Inflammation/Immunology Disease Research Fields Stephania japonica (Thunb.) Miers	Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 µM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

Cat. No.	Compare	Product Name	Species	Source

HY-P74210

	CYP3A4 Protein, Human (His) cytochrome P450 3A4; CYPIIIA3; CYP3A4; CYP3A3	Human	E. coli
	The CYP3A4 protein, encoded by the CYP3A4 gene, is a key enzyme in drug metabolism and the synthesis of cholesterol, steroids, and lipids. It localizes to the endoplasmic reticulum and is induced by glucocorticoids and certain drugs. CYP3A4 Protein, Human (His) is the recombinant human-derived CYP3A4 protein, expressed by E. coli , with N-His labeled tag. The total length of CYP3A4 Protein, Human (His) is 502 a.a., with molecular weight of ~59.2 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-133152S

Brexpiprazole S-oxide-d8

Brexpiprazole S-oxide-d₈ is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM[1][2][3].

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83620

	Cytochrome P450 3A4 Antibody (YA3365) HLP; CP33; CP34; CYP3A; NF-25; CYP3A3; P450C3; CYPIIIA3; CYPIIIA4; P450PCN1; CYP3A4	WB, IHC-P, IP	Human
	Cytochrome P450 3A4 Antibody (YA3365) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3365), targeting Cytochrome P450 3A4, with a predicted molecular weight of 57 kDa (observed band size: 57 kDa). Cytochrome P450 3A4 Antibody (YA3365) can be used for WB, IHC-P, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-115824

7ETMC		Alkynes
7ETMC is a cytochrome P450 inhibitor with selective inhibition of human cytochrome P450s 1A1 and 1A2. 7ETMC has inhibitory effects on P450s 1A1 and 1A2 with IC?? values of 0.46μM and 0.50μM, respectively, within the first six minutes, and has no inhibitory activity against P450s 2A6 and 2B1. Except for 7-ethynyl-3-methyl-4-phenylcoumarin, the remaining inhibitors show mechanism-based inhibition of P450s 1A1 and 1A2.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cytochrome P450 3A4

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products